Dec. 18, 2024
MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in therapies to restore, treat, and prevent hearing loss disorders, has announced promising data from the first two patients treated in the Audiogene Phase 1/2 clinical trial evaluating SENS-501. This trial focuses on infants and toddlers aged 6 to 31 months who suffer from a specific form of